ClinicalTrials.gg
RecruitingNCT07439107Updated Nov 12, 2026

Treatment Outcomes for Osteochondritis Dissecans of the Knee, Elbow and Ankle (OCD-MULTI): A Cohort Study

An observational study in Osteochondritis Dissecans (OCD), Osteochondritis Dissecans of the Knee and Osteochondritis Dissecans of the Elbow, sponsored by Peking University Third Hospital. Recruiting at 1 site in China. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Peking University Third Hospital · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
177
Ages
6 Years to 18 Years
Sex
All
01

Study summary

This is a single-centre, non-randomized, observational, bidirectional (retrospective and prospective) cohort study conducted at the Department of Sports Medicine of Peking University Third Hospital, Beijing. It enrols patients aged 6 to 18 years with magnetic resonance imaging (MRI)-confirmed osteochondritis dissecans (OCD) of the knee, elbow or ankle. The planned first analysis cohort comprises 177 participants: a retrospective cohort of 77 patients treated between January 2016 and 26 October 2025, and a prospective cohort of at least 100 participants enrolled consecutively from 27 October 2025 under an open-ended (rolling) recruitment policy with no fixed recruitment closing date, contingent on continued ethics approval, cohort infrastructure and funding; the registered completion date is maintained as an estimated date and updated as rolling enrolment proceeds.

Based on the treatment actually received, participants are classified into a conservative treatment group or a surgical treatment group; the surgical group is further categorized into six standard techniques. All comparisons are stratified by the affected joint.

The primary outcomes at 24 months are: (1) the Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score based on MRI in surgically treated participants; and (2) MRI-assessed stage regression in conservatively treated participants, using the Hefti staging for the knee, a five-stage T2-weighted MRI staging for the elbow (capitellum), and the Berndt-Harty classification (grades I, IIA, IIB, III and IV) for the ankle. Secondary outcomes are validated joint-specific functional measures (knee: IKDC Subjective Knee Form, Lysholm Knee Score and Tegner Activity Scale; elbow: Mayo Elbow Performance Score and QuickDASH; ankle: Foot and Ankle Outcome Score and AOFAS Ankle-Hindfoot Scale), pain on the visual analogue scale, reoperation and adverse events. All MRIs are independently read by radiologists/orthopaedic clinicians blinded to treatment assignment. Participants are followed for 24 months. The first locked prospective cohort (2030-12-31) forms the confirmatory analysis; participants enrolled after the first data-lock are analysed in prespecified periodic updates.

Read the detailed description

Design: This is a single-centre, non-randomized, observational ambidirectional cohort combining a retrospective cohort (patients treated from 1 January 2016 to 26 October 2025) with a consecutively enrolled prospective cohort (first participant enrolled 27 October 2025). The study is set in the Department of Sports Medicine of Peking University Third Hospital, and will be reported following the STROBE guideline. No treatment is assigned by the study; all treatment decisions are made by the treating clinician and patient according to current guidelines and individual circumstances, before and independently of study participation.

Participants: Males and females aged 6 to 18 years (inclusive) with a clinical and MRI diagnosis of OCD of the knee, elbow or ankle who receive treatment at the department are eligible. The prospective cohort uses non-probability consecutive sampling: every eligible, consenting patient is screened in chronological order and enrolled, with no fixed enrolment closing date. The retrospective cohort is identified from the institutional electronic medical record using the same eligibility criteria, with data extracted from existing records under a separate ethics approval.

Exposure definition: Participants are classified by the treatment actually received. Conservative management may include activity/sports restriction, bracing or short-term immobilization, protected weight-bearing, supervised physiotherapy, therapeutic ultrasound, analgesic/anti-inflammatory medication and traditional Chinese medicine. Surgical treatment comprises one of six standard procedures: (1) arthroscopic debridement; (2) fragment internal fixation; (3) subchondral/retroarticular drilling; (4) microfracture; (5) autogenous osteochondral transplantation; and (6) allogeneic osteochondral transplantation. Participants receiving multiple procedures are classified by the primary reconstructive procedure.

Imaging and staging: All joints undergo a standardized institutional MRI protocol at baseline and at 3, 6, 12 and 24 months. Lesion stability is staged on MRI using the Hefti system (stages I-V) for the knee, a five-stage T2-weighted MRI staging for the capitellum (I: normal contour with spotted high signal; II: more extensive high signal; III: discontinuity of the chondral surface without a high-signal interface; IV: a high-signal line separating the lesion; V: displacement or defect), and the Berndt-Harty classification for the talus (I: intact cartilage with subchondral injury; IIA: subchondral cyst; IIB: transverse fracture line without fragment; III: non-displaced fragment surrounded by fluid; IV: displaced fragment). MRIs are read independently by two readers blinded to treatment, with disagreement resolved by consensus or a third reader; inter-rater reliability is reported using the intraclass correlation coefficient.

Outcomes and schedule: The primary structural outcome is the 24-month MOCART score (0-100; higher scores indicate better morphological repair, >70 good and >85 excellent) in surgical participants, and MRI stage regression in conservative participants. Joint-specific functional scales and the pain VAS are recorded at baseline, treatment day, 7 days, and 3, 6, 12 and 24 months. Adverse and serious adverse events, complications, reoperation and concomitant treatment are monitored from treatment initiation through the last visit. Height and weight are measured at baseline.

Covariates: Baseline data include age, sex, height, weight and body mass index, affected side and joint, sports type/frequency/duration and trigger, comorbidities and concomitant medication. Skeletal maturity (immature versus mature) is determined from age and, when needed, radiographs and clinical physeal assessment. Lesion size (cm2 on MRI), intra-articular location and MRI stability are assessed by blinded evaluators. Lesion stability and skeletal maturity are prespecified effect modifiers; lesion size and joint are additional exploratory effect modifiers.

Governance: The study is sponsored by Peking University Third Hospital and overseen by a study management group chaired by the principal investigator, which reviews enrolment, data quality and adverse events at least annually and at every ethics renewal. Continuing recruitment is conditional on renewed ethics approval, maintained infrastructure and funding; the study will stop enrolling if approval or funding ceases, if the protocol can no longer be delivered to standard, or when a final analysis plan is adopted, without affecting follow-up of participants already enrolled.

02

Conditions studied

  • Osteochondritis Dissecans (OCD)
  • Osteochondritis Dissecans of the Knee
  • Osteochondritis Dissecans of the Elbow
  • Osteochondral Lesion of the Talus

Keywords

  • Osteochondritis Dissecans
  • treatment
  • MOCART
  • Joint function
03

In context

Osteochondritis Dissecans

31 studies on the registry are indexed under Osteochondritis Dissecans; 9 are open to participants now.

This study's planned enrollment of 177 is above the median of 130 across 12 observational studies indexed under Osteochondritis Dissecans.

Browse Osteochondritis Dissecans studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 275 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study aims to establish a cohort for the treatment of osteochondritis dissecans (OCD) of the knee, elbow and ankle joint. The target population consists of patients with OCD who have been diagnosed through clinical and imaging (MRI) examinations and are treated at the Department of Sports Medicine of Peking University Third Hospital. The age range is from 6 years old to 18 years old (inclusive).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of osteochondritis dissecans of the knee;
  • No participation in any other clinical trial within the past 3 months;
  • Voluntary participation, provision of signed , and ability to comply with the clinical follow-up schedule.

Exclusion criteria

Exclusion Criteria:

  • Regular use of sedatives, hypnotics, anxiolytics, or other addictive substances;
  • Presence of severe primary diseases in the cardiovascular, cerebrovascular, hepatic, renal, or hematopoietic systems, or psychiatric disorders;
  • Inability or unwillingness to undergo prolonged and intensive postoperative rehabilitation;
  • Females who are planning pregnancy within the next 12 months, or who are currently breastfeeding or pregnant;
  • Individuals with specific beliefs or restrictions that preclude the use of medical devices derived from porcine sources (as some grafts/devices are porcine-derived);
  • to Magnetic Resonance Imaging (MRI) examination;
  • Individuals with psychiatric disorders impairing decision-making capacity, or any other condition deemed by the investigator to make participation inadvisable.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
177 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Conservative Management Cohort

    Patients in this cohort receive non-surgical management, which may include activity restriction, braces/orthoses, immobilizers/casts, therapeutic ultrasound, analgesics, anti-inflammatory medications, and/or Traditional Chinese Medicine (TCM).

    Other: Clinical Management for OCD (Observed)

  • Surgical Treatment Cohort

    Patients who undergo any of the following standard surgical procedures as part of their routine clinical care: joint debridement, internal fixation, retroarticular drilling, microfracture, autogenous transplantation, or allograft transplantation.

    Other: Clinical Management for OCD (Observed)

Interventions

  • OtherClinical Management for OCD (Observed)

    This is not an intervention assigned by the study. It encompasses the spectrum of standard conservative and surgical treatments that participants may receive as part of independent clinical care. The specific treatment each participant receives is documented and used to define the study cohorts for observational comparison.

06

What researchers measure

Primary outcomes

  1. Magnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score in surgical treatment cohort

    In this study, the MOCART score quantitatively assesses cartilage/osteochondral repair on MRI across nine dimensions, including integrity of the repaired tissue, surface appearance, signal intensity and integration with surrounding tissue. The total score ranges from 0 to 100; higher scores indicate better morphological repair, with scores \>70 defined as good and \>85 as excellent. This primary outcome applies to surgically treated participants across the knee, elbow and ankle.

    Time frame: preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.

  2. MRI stage regression in conservative treatment cohort

    Stage regression of the OCD lesion on serial MRI in conservatively treated participants, assessed by readers blinded to treatment using the joint-specific validated system: the Hefti staging (stages I-V) for the knee, a five-stage T2-weighted MRI staging (stages I-V) for the elbow capitellum, and the Berndt-Harty classification (grades I, IIA, IIB, III and IV) for the talus. Stage regression (a decrease in stage from baseline) indicates structural healing/stabilization and is summarized as the proportion with regression and the change in stage at 24 months.

    Time frame: preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.

Secondary outcomes

  1. Tegner Activity Scale

    It is a one-dimensional scale ranging from 0 to 10, used to assess the activity level of patients in terms of sports and daily work. The higher the score, the higher the activity level of knee joint. High score (8-10 points): Indicates the level of competitive sports, with extremely high requirements for the knee joint. Medium score (4-7 points): Represents recreational sports and physical labor, which is the level of most active people. Low score (0-3 points): Represents daily life and sedentary work, with a lower load on the knee joint.

    Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

  2. International Knee Documentation Committee (IKDC)-2000

    It can comprehensively assess the knee joint's functionality, consisting of 18 questions, covering three dimensions: symptoms, sports activity function, and daily activity function. The higher the score, the better the knee joint's functionality and the fewer the symptoms. Generally, a score of \>90 indicates excellent function, while a score of \<70 indicates significant functional impairment. The minimum clinically important difference is approximately 10-12 points.

    Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

  3. Lysholm Knee Score

    It can assess specific symptoms and functional impairments of the knee joint, and has particular advantages in reflecting instability and limitations in daily activities. It consists of 8 items, with a total score of 100. The higher the score, the better the function. Function classification (widely accepted standard): Excellent: 95 - 100 points; Good: 84 - 94 points; Average: 65 - 83 points; Poor: \< 65 points.

    Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

  4. Visual Analog Scale

    It can quantify the intensity of subjective pain and is the simplest and most direct method for pain assessment. It is usually a horizontal line 10 centimeters long, with "no pain" marked at the left end (0 points) and "the most intense pain" marked at the right end (10 points). The patient marks their own sensation on the line. 0 points: No pain. 1-3 points: Mild pain (not affecting sleep). 4-6 points: Moderate pain (affects sleep but is tolerable). 7-10 points: Severe pain (extremely unbearable, seriously affecting sleep and daily life).

    Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

  5. Mayo Elbow Performance Score (MEPS)

    The Mayo Elbow Performance Score (MEPS) is a standardized clinician- and patient-reported composite outcome measure used to assess elbow-specific symptoms and functional impairment. It evaluates four domains: pain (0-45 points), range of motion/flexion-extension arc (0-20 points), joint stability (0-10 points), and ability to perform daily activities (0-25 points; combing hair, feeding, hygiene, donning shirt, donning shoes). The total score ranges from 0 to 100, with higher scores indicating better elbow function and less disability. Function classification: Excellent: 90-100 points; Good: 75-89 points; Fair: 60-74 points; Poor: \<60 points.

    Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

  6. Quick DASH

    The Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) is a shortened, validated patient-reported outcome measure assessing upper-extremity symptoms and functional impairment. It consists of 11 items covering difficulty with physical activities, pain, tingling, sleep disturbance, and limitations in work and social activities. Each item is rated on a 5-point Likert scale from 1 (no difficulty/no symptom) to 5 (unable/extreme symptom). At least 10 of 11 items must be completed for scoring. The score is transformed to a 0-100 scale using the formula: \[(mean of completed items - 1) × 25\]. The total score ranges from 0 to 100, where 0 indicates no disability and 100 indicates the most severe upper-extremity disability. Higher scores represent worse function.

    Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

  7. Foot and Ankle Outcome Score (FAOS)

    The Foot and Ankle Outcome Score (FAOS) is a patient-reported outcome measure assessing foot- and ankle-related pain, symptoms, daily function, sports/recreation function, and quality of life. It consists of 42 items divided into five subscales: Pain (9 items), Other Symptoms (7 items), Activities of Daily Living (17 items), Sport and Recreation (5 items), and Foot- and Ankle-Related Quality of Life (4 items). Each item is scored on a 5-point Likert scale from 0 (no problem) to 4 (extreme problem). Each subscale is normalized to a 0-100 scale, where 100 indicates no symptoms or functional limitation and 0 indicates the worst possible state. Higher subscale scores indicate better foot and ankle function. A total FAOS score is not routinely derived; subscales are reported separately.

    Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

  8. American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale

    The American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Scale is a clinician- and patient-assessed composite measure evaluating clinical status of the ankle and hindfoot. It includes 9 items in three domains: Pain (1 item, 0-40 points), Function (7 items, 0-50 points; activity limitation/support, walking distance, walking surfaces, gait, sagittal motion, hindfoot motion, stability), and Alignment (1 item, 0-10 points). The total score ranges from 0 to 100, with 100 indicating no pain, full function, and good alignment. Higher scores indicate better clinical outcome. Commonly used classification: Excellent 90-100; Good 75-89; Fair 50-74; Poor \<50.

    Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

Other outcomes

  1. Height

    Time frame: Preoperatively

  2. Weight

    Time frame: Preoperatively

  3. AE/SAE

    This study will systematically monitor and record all adverse events and serious adverse events that occur from the start of treatment until the last follow-up. Adverse events refer to any adverse medical events that occur in patients after receiving treatment. These include, but are not limited to, common complications related to surgery, failure of cartilage repair, joint stiffness, and activity impairment. Serious adverse events include situations that result in death, endanger life, require hospitalization, cause significant functional impairment, or other important medical events.

    Time frame: postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Jan 2026 → Oct 2025 and completion Dec 2028 → Dec 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2025
First posted
Feb 27, 2026
StartActual
Oct 27, 2025was Jan 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2030was Dec 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Nov 12, 2026
Sites
Peking University Third Hospital is now Recruiting
Nov 12, 2026
Start date
Jan 1, 2026→Oct 27, 2025
Nov 12, 2026
Study completion
Dec 31, 2028→Dec 31, 2030
Nov 12, 2026
Enrollment
254→177
Nov 12, 2026
Eligibility
Maximum age 40 Years→18 Years
Nov 12, 2026
Primary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedMagnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score in surgical treatment cohortTime frame: preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.
  • AddedMRI stage regression in conservative treatment cohortTime frame: preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.
Nov 12, 2026
Secondary outcomes
4 added
What changed in the outcomes
  • AddedMayo Elbow Performance Score (MEPS)Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
  • AddedQuick DASHTime frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
  • AddedFoot and Ankle Outcome Score (FAOS)Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
  • AddedAmerican Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot ScaleTime frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
Nov 12, 2026
Contact
Study contact now listed: added z•••@bjmu.edu.cn · •••3917. See the current contact
Nov 12, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Peking University Third Hospital · Beijing, ChinaContact added z•••@bjmu.edu.cn · •••3917
Nov 12, 2026
Title
Treatment Outcomes for Osteochondritis Dissecans of the Knee, Elbow and Ankle (OCD-MULTI): A Cohort Study
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Active, not recruiting→Recruiting
    Peking University Third Hospital is now Recruiting
    Start date Jan 1, 2026→Oct 27, 2025
    Study completion Dec 31, 2028→Dec 31, 2030
    Enrollment 254→177
    Eligibility Maximum age 40 Years→18 Years
    Primary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedMagnetic Resonance Observation of Cartilage Repair Tissue (MOCART) score in surgical treatment cohortTime frame: preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.
    • AddedMRI stage regression in conservative treatment cohortTime frame: preoperatively, and postoperatively at 3 months, 6 months, 12 months, and 24 months.
    Secondary outcomes 4 added
    What changed in the outcomes
    • AddedMayo Elbow Performance Score (MEPS)Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
    • AddedQuick DASHTime frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
    • AddedFoot and Ankle Outcome Score (FAOS)Time frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
    • AddedAmerican Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot ScaleTime frame: preoperatively and postoperatively at 7 days, 3 months, 6 months, 12 months, and 24 months.
    Contact Study contact now listed: added z•••@bjmu.edu.cn · •••3917. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Peking University Third Hospital · Beijing, ChinaContact added z•••@bjmu.edu.cn · •••3917
    Title Treatment Outcomes for Osteochondritis Dissecans of the Knee, Elbow and Ankle (OCD-MULTI): A Cohort Study
    + 3 other changes: verification date, description and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07439107
Responsible party
Liu Zhenlong (Associate Chief Physician, Peking University Third Hospital) — Principal investigator
First posted
Feb 27, 2026
Start date
Oct 27, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Zhenglong Liu, Dr
Contact
zhenlong_liu@bjmu.edu.cn
86+13261993917

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion